GDF15: Immunomodulatory Role in Hepatocellular Carcinoma Pathogenesis and Therapeutic Implications
Yi-Ning Du,Jin-Wei Zhao
DOI: https://doi.org/10.2147/jhc.s471239
2024-06-20
Journal of Hepatocellular Carcinoma
Abstract:Yi-Ning Du, 1 Jin-Wei Zhao 2 1 Department of Medical Sciences, Li Ka-shing School of Medicine, University of Hong Kong, Hong Kong, People's Republic of China; 2 Department of Hepatopancreatobiliary Surgery, Second Hospital of Jilin University, Jilin University, Changchun, Jilin Province, People's Republic of China Correspondence: Jin-Wei Zhao, Department of Hepatopancreatobiliary Surgery, Second Hospital of Jilin University, Jilin University, No. 218, Ziqiang Road, Changchun, 130000, Jilin Province, People's Republic of China, Tel +8615844089385, Email Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths globally and the sixth most common cancer worldwide. Evidence shows that growth differentiation factor 15 (GDF15) contributes to hepatocarcinogenesis through various mechanisms. This paper reviews the latest insights into the role of GDF15 in the development of HCC, its role in the immune microenvironment of HCC, and its molecular mechanisms in metabolic dysfunction associated steatohepatitis (MASH) and metabolic associated fatty liver disease (MAFLD)-related HCC. Additionally, as a serum biomarker for HCC, diagnostic and prognostic value of GDF15 for HCC is summarized. The article elaborates on the immunological effects of GDF15, elucidating its effects on hepatic stellate cells (HSCs), liver fibrosis, as well as its role in HCC metastasis and tumor angiogenesis, and its interactions with anticancer drugs. Based on the impact of GDF15 on the immune response in HCC, future research should identify its signaling pathways, affected immune cells, and tumor microenvironment interactions. Clinical studies correlating GDF15 levels with patient outcomes can aid personalized treatment. Additionally, exploring GDF15-targeted therapies with immunotherapies could improve anti-tumor responses and patient outcomes. Keywords: growth differentiation factor 15, GDF15, hepatocellular carcinoma, HCC, immune suppression, immunotherapy GDF15, also known as macrophage inhibitory factor-1 (MIC-1), prostate-derived factor (PDF), and others, is a member of the transforming growth factor (TGF) superfamily. 1–3 It forms a pro-GDF15 homodimer in the endoplasmic reticulum (ER) through disulfide bond formation. After proteolytic secretion in the ER, mature homodimeric GDF15 is released from its propeptide. 4 Other members of the GDF family, such as GDF1, GDF3, GDF5, GDF7, and GDF10 are predominantly regulators of cell growth and differentiation in embryonic and adult tissues, and even play a role in skeletal morphogenesis. Silencing of GDF1 expression significantly inhibited the GDF1-SMAD2/3 pathway, demonstrating the role of GDF1 in inhibiting gastric cancer progression. 5 GDF3 regulates cell fate in stem cells and early embryos. 6 GDF5 would be involved in the pathogenesis of osteoarthritis. 7,8 GDF7 can promote the differentiation in vitro of two dorsal sensory interneuron classes. 9 GDF15 was first identified from a cDNA library enriched for genes linked to macrophages. 1 Paralkar et al discovered it using a probe for human transforming growth factor placental (hTGF-PL), naming it GDF15. 10 Its role in cancer has been suggested, showing various functions mainly involved in regulating anti-inflammatory and apoptotic pathways. 11 GFRAL is a specific receptor for GDF15, belonging to the GDNF family receptor α (GFR-α) group within the TGF-β superfamily. 3 It's mainly found in hindbrain neurons, exclusively serving as the receptor for GDF15 in the brainstem. 12 To instigate intracellular signaling upon GDF15 activation, GFRAL necessitates binding to the co-receptor proto-oncogene tyrosine-protein kinase receptor RET, and signals through the extracellular-signal related kinase (ERK) and AKT/protein kinase B pathways, without activating canonical TGF-β signaling pathways. 13,14 The disparity has been attributed to the presence of TGF-β impurities in several commercially available recombinant GDF15 preparations, considering that TGF-β may induce significant biological effects within the millimolar concentration range. 15 HCC is the third most prominent contributor to cancer-associated mortality worldwide. 16 Data based on prevalence and population attributable scores from different regions suggest that 44% of HCC cases worldwide were attributable to chronic hepatitis B infection, with the majority of cases occurring in Asia. 17 Hepatitis C was responsible for 21% of cases. 17 The development of HCC is largely determined by a variety of key risk factors, including alcohol, obesity, smoking, persistent infection with hepatitis B and C viruses, and the combined effects of MASH and MAFLD transformation. 1 -Abstract Truncated-
oncology